Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Partners of the Pierre Fabre Group: from health to beauty
Fight against cancer : our therapeutic responses | Pierre Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology | Evaluate
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Puma regains China rights to Nerlynx and amends deal with Fabre
Accord entre Pierre Fabre et Puma Biotechnology
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
THE FACES OF BREAST CANCER
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Pierre Fabre & NERLYNX commercialisation | Nerlynx
Pierre Fabre engagements | NERLYNX
Partners of the Pierre Fabre Group: from health to beauty
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
